1. Two-year outcome data suggest that less invasive surfactant administration (LISA) is safe. Results from the follow-up of the randomized controlled AMV (avoid mechanical ventilation) study
- Author
-
Egbert Herting, Jens Möller, Wolfgang Göpel, Ursula Weller, Thomas Hoehn, Bernhard Roth, Axel von der Wense, Matthias Vochem, Christian Wieg, Angela Kribs, and Christoph Härtel
- Subjects
Male ,medicine.medical_treatment ,Short Communication ,Less invasive ,LISA – CPAP ,law.invention ,Catheterization ,03 medical and health sciences ,0302 clinical medicine ,Pulmonary surfactant ,Randomized controlled trial ,law ,030225 pediatrics ,medicine ,Humans ,030212 general & internal medicine ,Growth Disorders ,Outcome ,Mechanical ventilation ,Respiratory Distress Syndrome, Newborn ,Continuous Positive Airway Pressure ,business.industry ,Premature infants ,Standard treatment ,Infant, Newborn ,Pulmonary Surfactants ,Respiration, Artificial ,Catheter ,Treatment Outcome ,Neurodevelopmental Disorders ,Anesthesia ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Breathing ,Female ,Less invasive surfactant ,Outcome data ,business ,Infant, Premature ,Follow-Up Studies - Abstract
Less invasive surfactant administration (LISA) is a method to deliver surfactant to spontaneously breathing premature infants via a thin catheter. Here we report the two-year outcome from the AMV (avoid mechanical ventilation) study, the first randomized controlled trial on this mode of surfactant delivery. No statistically significant differences in weight, length or neurodevelopmental outcome (Bayley II scores) were found between the LISA intervention group (n = 95) and the control group (n = 84) that received standard treatment.Conclusion: No differences in outcome were observed at 2 years. LISA seems safe in that aspect. What is Known:• LISA is a method that is in increasing use for surfactant delivery to spontaneously breathing infants. LISA reduces the need for mechanical ventilation. What is New:• Outcome data at 2 years from the first randomized study with LISA raise no safety concerns in comparison to a group of infants that received standard treatment.
- Published
- 2020